论文部分内容阅读
背景与目的:Ⅲ期和高危Ⅱ期结直肠癌患者术后接受辅助化疗已得到越来越多临床医生的认可,但在临床实践中我们发现只有部分患者最终完成半年的辅助化疗,本研究的目的是分析我院Ⅲ期和高危Ⅱ期结直肠癌患者术后辅助化疗的时间,探讨结直肠癌术后辅助化疗时间对3年无病生存期的影响。方法:收集并分析2003年7月至2007年12月间在中山大学肿瘤防治中心确诊的Ⅲ期和高危Ⅱ期结直肠癌患者276例,所有患者均接受了根治性手术,术后接受了含有5-FU/CF或希罗达或替加氟±奥沙利铂方案化疗至少2疗程。结果:276例患者中有216例接受含有奥沙利铂方案的化疗,另外60例接受希罗达或5-FU/CF或替加氟的化疗。216例患者中只有49例(22.7%)最终完成了半年的辅助化疗。单因素和多因素分析均显示术后辅助化疗时间、年龄、性别、淋巴结N分期、病理分化程度是影响3年无病生存期的独立因素(P<0.05)。结论:结直肠癌患者术后辅助化疗时间是3年无病生存期的独立影响因素。
BACKGROUND & OBJECTIVE: More and more clinicians have accepted the adjuvant chemotherapy for patients with stage Ⅲ and high risk stage Ⅱ colorectal cancer after operation. However, in clinical practice, we found that only some patients eventually completed six months of adjuvant chemotherapy. The purpose of this study was to analyze the time of postoperative adjuvant chemotherapy in patients with stage Ⅲ and high risk Ⅱ colorectal cancer and to investigate the effect of postoperative adjuvant chemotherapy for colorectal cancer on 3-year disease-free survival. Methods: A total of 276 patients with stage Ⅲ and high-risk stage Ⅱ colorectal cancer diagnosed at Cancer Center of Sun Yat-sen University from July 2003 to December 2007 were collected and analyzed. All patients underwent radical surgery. 5-FU / CF or Xeloda or Tegafur ± oxaliplatin regimen for at least 2 cycles of chemotherapy. RESULTS: Of the 276 patients, 216 received oxaliplatin-containing chemotherapy and the other 60 received chemotherapy with xeloda or 5-FU / CF or tegafur. Only 49 of the 216 patients (22.7%) eventually completed six months of adjuvant chemotherapy. Univariate and multivariate analysis showed that postoperative adjuvant chemotherapy time, age, gender, lymph node N stage and pathological differentiation were the independent factors affecting the 3-year disease-free survival (P <0.05). Conclusion: The postoperative adjuvant chemotherapy time in patients with colorectal cancer is an independent influencing factor of 3-year disease-free survival.